Cargando…

Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss

BACKGROUND: Health systems face challenges to accelerate access to innovations that add value and avoid those unlikely to do so. This is very timely to the field of age-related sensorineural hearing loss (ARHL), where a significant unmet market need has been identified and sizeable investments made...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, Evie C., Scholte, Mirre, Su, Matthew P., Horstink, Yvette, Mandavia, Rishi, Rovers, Maroeska M., Schilder, Anne G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930912/
https://www.ncbi.nlm.nih.gov/pubmed/35310110
http://dx.doi.org/10.3389/fnins.2022.769983
_version_ 1784671139583229952
author Landry, Evie C.
Scholte, Mirre
Su, Matthew P.
Horstink, Yvette
Mandavia, Rishi
Rovers, Maroeska M.
Schilder, Anne G. M.
author_facet Landry, Evie C.
Scholte, Mirre
Su, Matthew P.
Horstink, Yvette
Mandavia, Rishi
Rovers, Maroeska M.
Schilder, Anne G. M.
author_sort Landry, Evie C.
collection PubMed
description BACKGROUND: Health systems face challenges to accelerate access to innovations that add value and avoid those unlikely to do so. This is very timely to the field of age-related sensorineural hearing loss (ARHL), where a significant unmet market need has been identified and sizeable investments made to promote the development of novel hearing therapeutics (NT). This study aims to apply health economic modeling to inform the development of cost-effective NT. METHODS: We developed a decision-analytic model to assess the potential costs and effects of using regenerative NT in patients ≥50 with ARHL. This was compared to the current standard of care including hearing aids and cochlear implants. Input data was collected from systematic literature searches and expert opinion. A UK NHS healthcare perspective was adopted. Three different but related analyses were performed using probabilistic modeling: (1) headroom analysis, (2) scenario analyses, and (3) threshold analyses. RESULTS: The headroom analysis shows an incremental net monetary benefit (iNMB) of £20,017[£11,299–£28,737] compared to the standard of care due to quality-adjusted life-years (QALY) gains and cost savings. Higher therapeutic efficacy and access for patients with all degrees of hearing loss yields higher iNMBs. Threshold analyses shows that the ceiling price of the therapeutic increases with more severe degrees of hearing loss. CONCLUSION: NT for ARHL are potentially cost-effective under current willingness-to-pay (WTP) thresholds with considerable room for improvement in the current standard of care pathway. Our model can be used to help decision makers decide which therapeutics represent value for money and are worth commissioning, thereby paving the way for urgently needed NT.
format Online
Article
Text
id pubmed-8930912
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89309122022-03-19 Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss Landry, Evie C. Scholte, Mirre Su, Matthew P. Horstink, Yvette Mandavia, Rishi Rovers, Maroeska M. Schilder, Anne G. M. Front Neurosci Neuroscience BACKGROUND: Health systems face challenges to accelerate access to innovations that add value and avoid those unlikely to do so. This is very timely to the field of age-related sensorineural hearing loss (ARHL), where a significant unmet market need has been identified and sizeable investments made to promote the development of novel hearing therapeutics (NT). This study aims to apply health economic modeling to inform the development of cost-effective NT. METHODS: We developed a decision-analytic model to assess the potential costs and effects of using regenerative NT in patients ≥50 with ARHL. This was compared to the current standard of care including hearing aids and cochlear implants. Input data was collected from systematic literature searches and expert opinion. A UK NHS healthcare perspective was adopted. Three different but related analyses were performed using probabilistic modeling: (1) headroom analysis, (2) scenario analyses, and (3) threshold analyses. RESULTS: The headroom analysis shows an incremental net monetary benefit (iNMB) of £20,017[£11,299–£28,737] compared to the standard of care due to quality-adjusted life-years (QALY) gains and cost savings. Higher therapeutic efficacy and access for patients with all degrees of hearing loss yields higher iNMBs. Threshold analyses shows that the ceiling price of the therapeutic increases with more severe degrees of hearing loss. CONCLUSION: NT for ARHL are potentially cost-effective under current willingness-to-pay (WTP) thresholds with considerable room for improvement in the current standard of care pathway. Our model can be used to help decision makers decide which therapeutics represent value for money and are worth commissioning, thereby paving the way for urgently needed NT. Frontiers Media S.A. 2022-03-04 /pmc/articles/PMC8930912/ /pubmed/35310110 http://dx.doi.org/10.3389/fnins.2022.769983 Text en Copyright © 2022 Landry, Scholte, Su, Horstink, Mandavia, Rovers and Schilder. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Landry, Evie C.
Scholte, Mirre
Su, Matthew P.
Horstink, Yvette
Mandavia, Rishi
Rovers, Maroeska M.
Schilder, Anne G. M.
Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss
title Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss
title_full Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss
title_fullStr Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss
title_full_unstemmed Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss
title_short Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss
title_sort early health economic modeling of novel therapeutics in age-related hearing loss
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930912/
https://www.ncbi.nlm.nih.gov/pubmed/35310110
http://dx.doi.org/10.3389/fnins.2022.769983
work_keys_str_mv AT landryeviec earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss
AT scholtemirre earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss
AT sumatthewp earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss
AT horstinkyvette earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss
AT mandaviarishi earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss
AT roversmaroeskam earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss
AT schilderannegm earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss